Seres Therapeutics (NASDAQ:MCRB) Insider Sells $21,746.10 in Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB) insider Matthew Henn sold 1,257 shares of Seres Therapeutics stock in a transaction on Saturday, November 15th. The shares were sold at an average price of $17.30, for a total value of $21,746.10. Following the sale, the insider directly owned 7,527 shares of the company’s stock, valued at approximately $130,217.10. This trade represents a 14.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Seres Therapeutics Trading Up 14.2%

Shares of MCRB traded up $3.07 during midday trading on Tuesday, reaching $24.71. 890,977 shares of the stock were exchanged, compared to its average volume of 121,438. The company has a market capitalization of $223.55 million, a P/E ratio of -5.48 and a beta of 0.19. Seres Therapeutics, Inc. has a 52 week low of $6.53 and a 52 week high of $25.85. The company’s 50 day moving average is $17.74 and its two-hundred day moving average is $13.97.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on MCRB shares. Weiss Ratings restated a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday. Canaccord Genuity Group lifted their price objective on shares of Seres Therapeutics from $14.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Seres Therapeutics presently has a consensus rating of “Reduce” and an average price target of $14.33.

Institutional Trading of Seres Therapeutics

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE boosted its holdings in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,157 shares in the last quarter. XTX Topco Ltd purchased a new stake in Seres Therapeutics during the second quarter valued at approximately $249,000. Schonfeld Strategic Advisors LLC acquired a new stake in Seres Therapeutics in the third quarter valued at approximately $557,000. Goldman Sachs Group Inc. grew its holdings in Seres Therapeutics by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 21,679 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Seres Therapeutics in the second quarter worth $1,016,000. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.